Literature DB >> 1649870

From the National Institutes of Health. Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS.

B E Laughon1, H S Allaudeen, J M Becker, W L Current, J Feinberg, J K Frenkel, R Hafner, W T Hughes, C A Laughlin, J D Meyers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1649870     DOI： 10.1093/infdis/164.2.244

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  11 in total

1.  Rifapentine is active in vitro and in vivo against Toxoplasma gondii.

Authors:  F G Araujo; A A Khan; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 2.  Beige mouse model for Mycobacterium avium complex disease.

Authors:  P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

3.  Insertional mutagenesis and marker rescue in a protozoan parasite: cloning of the uracil phosphoribosyltransferase locus from Toxoplasma gondii.

Authors:  R G Donald; D S Roos
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

4.  The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.

Authors:  F G Araujo; A A Khan; T L Slifer; A Bryskier; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Mining the Plasmodium genome database to define organellar function: what does the apicoplast do?

Authors:  David S Roos; Michael J Crawford; Robert G K Donald; Martin Fraunholz; Omar S Harb; Cynthia Y He; Jessica C Kissinger; Michael K Shaw; Boris Striepen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-01-29       Impact factor: 6.237

6.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Requirements for CD4+ cells and gamma interferon in resolution of established Cryptosporidium parvum infection in mice.

Authors:  W Chen; J A Harp; A G Harmsen
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells.

Authors:  M Pourshafie; Q Ayub; W W Barrow
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

9.  Gamma interferon functions in resistance to Cryptosporidium parvum infection in severe combined immunodeficient mice.

Authors:  W Chen; J A Harp; A G Harmsen; E A Havell
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

10.  Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.

Authors:  S T Brown; F F Edwards; E M Bernard; W Tong; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.